Sample Submission Form

Lung Adenocarcinoma Cell (LUAD)

Instructions: *This form should be completed for all submitted cases, prior to the shipment of samples to the BCR.* ***Questions regarding this form should be directed to the Tissue Source Site's Clinical Outreach Contact at the BCR.***

Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

Tissue Source Site (TSS): _____ TSS ID: _____ TSS Unique Patient ID: _____

Interviewer Name: _____ Interview Date ___ ___/___ ___ /___ ___ ___ ___

#	Question	Entry Alternatives	Working Instructions
STOP	**Verification of Requirements** Prior to the shipment of samples to the BCR, the TSS must answer the following questions to verify that all requirements are met.		
1	Type of Biospecimen Submission *(check all that apply)*	☐ Primary Tumor ☐ Normal Control	Please provide the type of biospecimen(s) being submitted at the time of completion of this form.
Consent Information			
2	Consent Status	☐ Formally Consented ☐ Consented by Death ☐ Exemption *(see note at right)* ☐ Waiver *(see note at right)*	Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. Exemptions and waivers for consent must be approved by NCI. 3288361
3	Date of Formal Consent	_____ _____ _____ _____ _____ _____ _____ _____ *Month* *Day* *Year*	If the patient was formally consented, provide the date of consent. Do not complete if the patient consented by death. 3081955 (month), 3081957 (day), 3081959 (year)
4	Date of Death	_____ _____ _____ _____ _____ _____ _____ _____ *Month* *Day* *Year*	If the patient consented by death (i.e. they did not formally consent), provide the date of death. Do not complete if the patient formally consented. 2897026 (month), 2897028 (day), 2897030 (year)
History of Malignancies			
5	History of Other Malignancy *(Including ALL Prior and Synchronous Malignancies)*	☐ None ☐ Prior Malignancy ☐ Synchronous Malignancy ☐ Both Synchronous and Prior Malignancy	Indicate whether the patient has a history of malignancies, including synchronous or bilateral malignancies. Please complete an Other Malignancy Form (OMF) for each malignancy diagnosed prior to or at the time the submitted tissue was procured. If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, only complete an OMF for the initial diagnosis of each of these types. 3382736
Neoadjuvant Treatment			
6	History of Neoadjuvant Treatment (prior to procurement) of Tumor Submitted	☐ None ☐ Radiation prior to sample procurement* ☐ Pharmaceutical treatment prior to sample procurement* ☐ Both pharmaceutical and radiation treatment prior to sample procurement*	Indicate whether the patient received therapy for the tumor submitted prior to the sample procurement. If the patient did receive treatment prior to procurement, the TSS should contact the BCR for further instruction. *Systemic therapy and certain localized therapies (those administered to the same site as the submitted tissue) given prior to the procurement of the sample submitted are exclusionary. 3382737
Pathology Prescreen at the TSS			
7	Was the submitted sample prescreened at the TSS?	☐ Yes ☐ No	Indicate whether the sample submitted to the BCR was prescreened at the TSS. 3081942

Sample Submission Form

Lung Adenocarcinoma Cell (LUAD)

#	Question	Entry Alternatives	Working Instructions
8	Name of Pathologist *(person who performed the review of the submitted slide)*	_____	Provide the name of the pathologist who performed the review of the submitted sample. 3288225
9	Date of Pathology Prescreen	_____ _____ _____ _____ _____ _____ _____ _____ *Month* *Day* *Year*	Provide the date the pathologist performed the prescreen review. 3288224
10	Does the percent of tumor nuclei meet current project metrics?	☐ Yes, the tumor meets the current metrics. ☐ No, the tumor is being submitted for macrodissection.	Confirm that the malignant sample submitted to the BCR meets the current tumor nuclei metrics. If submitting for macrodissection, please contact the BCR prior to shipment. 3288520
11	Does the percent necrosis meet the current project metrics?	☐ Yes ☐ No	Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics. If submitting for macrodissection, please contact the BCR prior to shipment. 3288524
Initial Pathology Report			
12	Will a De-Identified Pathology Report Be Submitted?	☐ Yes ☐ No	Confirm that a de-identified pathology report is being sent to BCR prior to or with the shipment of the physical samples. Cases without a pathology report at the time of sample submission will be excluded. 3288292
13	Is the histologic diagnosis on the CQCF (as determined by the TSS pathology review of the submitted slide) consistent with the histology listed on the submitted pathology report?	☐ Yes ☐ No	Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR. If "yes," skip related question below. The diagnosis is considered to be consistent if at least one of the following criteria are met: 1) Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR. 2) Diagnosis on the CQCF includes at least one of the subtypes listed on the pathology report and all subtypes on the pathology report are acceptable. 3) Diagnosis on the CQCF is "histology, NOS" (i.e., Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histologic group. 4) Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable subtypes, provided that percent subtype(s) meet applicable disease-specific requirements. 3288300
15	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	☐ Macrodissection Performed *(see definition at right)* ☐ Other Pathology Review *(see definition at right)* ☐ Pathology Review for this Project *(see definition at right)*	If the diagnosis provided on this form is not consistent with the final diagnosis found on the pathology report provided, specify a reason for this inconsistency. 1.) Macrodissection that was performed at the TSS to select a region containing an acceptable diagnosis determined a specific histological subtype that is different from the original pathology report 2.) The pathology analysis performed at the TSS determined a specific histological subtype that is different from the original pathology report 3.) The pathology review of the frozen section for this project determined that the histologic subtype is different from the pathology report If a TSS pathology review of the submitted sample resulted in a different histologic subtype than what is documented on the original pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "Pathologic Diagnosis Discrepancy Form". In the case of diagnosis modifications, institution protocol should be followed for proper quality assurance. 3288315

Sample Submission Form

Lung Adenocarcinoma Cell (LUAD)

#	Question	Entry Alternatives	Working Instructions
Demographic Information			
15	Date of Birth	_____ _____ _____ _____ _____ _____ _____ _____ *Month* *Day* *Year*	Provide the date the patient was born. 2896950(month), 2896952(day), 2896954 (year)
16	Race	☐ American Indian or Alaska Native ☐ Asian ☐ Black or African American ☐ Native Hawaiian or other Pacific Islander ☐ White ☐ Unknown	Provide the patient's race using the provided categories, as defined below. **American Indian or Alaska Native:** A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. **Asian:** A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. **White:** A person having origins in any of the original peoples of the far Europe, the Middle East, or North Africa. **Black or African American:** A person having origins in any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American." **Native Hawaiian or other Pacific Islander:** A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. **Unknown** 2192199
17	Ethnicity	☐ Not Hispanic or Latino ☐ Hispanic or Latino ☐ Unknown	Provide the patient's ethnicity using the provided categories, defined below: **Not Hispanic or Latino:** A person not meeting the definition of Hispanic or Latino. **Hispanic or Latino:** A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. **Unknown** 2192217
Tumor Information The following information must be completed for the tumor sample submitted and should be answered specifically about the submitted sample(s). If multiple vials of the tumor sample are submitted, the "Tumor Sample Information" must be completed for each vial submitted to the BCR.			
Pathologic/Anatomic Information			
18	Is a primary tumor being submitted?	☐ Yes, Primary Tumor	Indicate whether a primary tumor is being submitted to the BCR. 3288124
19	Tumor Category	☐ Primary	Confirm that the sample submitted is a primary biospecimen. 3288124
20	Histological Subtype	☐ Adenocarcinoma, Mixed Subtype ☐ Acinar Adenocarcinoma ☐ Papillary Adenocarcinoma ☐ Bronchioloalveolar Carcinoma, Mucinous ☐ Bronchioloalveolar Carcinoma, Non-Mucinous ☐ Solid Pattern Predominant Adenocarcinoma ☐ Micropapillary Adenocarcinoma ☐ Fetal Adenocarcinoma ☐ Mucinous Cystadenocarcinoma ☐ Mucinous (Colloid) Adenocarcinoma ☐ Signet Ring Adenocarcinoma ☐ Clear Cell Adenocarcinoma ☐ Adenocarcinoma, Not Otherwise Specified (NOS)	Indicate the histologic subtype of the malignant sample submitted. 3081934
1	Anatomic Site of Submitted Sample	☐ Lung	Indicate the anatomic site of the tumor biospecimen submitted. 2735776
22	Region of Submitted Sample *(Check all that apply)*	☐ Upper Lobe ☐ Middle Lobe (right only) ☐ Lower Lobe ☐ Unknown	Indicate the region of the anatomic site of the tumor biospecimen submitted. 3081961
23	Laterality	☐ Left ☐ Right	Indicate the laterality of the tumor biospecimen submitted. 827

Sample Submission Form

Lung Adenocarcinoma Cell (LUAD)

#	Question	Entry Alternatives	Working Instructions
Diagnosis Information			
24	Date of Initial Pathologic Diagnosis	_____ _____ _____ _____ _____ _____ _____ _____ *Month* *Day* *Year*	Provide the date the patient was initially pathologically diagnosed with the malignancy submitted. 2896956 (month), 2896958(day), 2896960 (year)
Tumor Procurement Information			
25	Date of Tumor Sample Procurement	_____ _____ _____ _____ _____ _____ _____ _____ *Month* *Day* *Year*	Provide the date the submitted tumor sample was procured. 3008197 (month), 3008195(day), 3008199 (year)
26	Method of Tumor Sample Procurement	☐ Pneumonectomy ☐ Lobectomy ☐ Wedge Resection ☐ Biopsy (all types) ☐ Other Surgical Resection	Indicate the procedure performed to obtain the tumor sample that is being submitted. 3103514
27	Country where Tumor Sample was Procured	_____	Provide the country where the submitted tumor sample was procured.. 3152016
Tumor Sample Information If multiple vials of the tumor sample are submitted, this section must be completed for each vial submitted to the BCR.			
28	Tumor Identifier	_____	Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor sample needs a unique ID. 3288096
29	Weight of Frozen Tumor Sample	_____ (mg) (0.2 cm^3 (0.6cm * 0.6cm *0.6cm) ≈ 200mg	Provide the weight of the tumor sample submitted. Weight can be estimated based on the size of the tumor submitted. 3081946
30	Tumor Nuclei Percent (%) of Frozen Tumor Sample	_____ (%)	Provide the percent of tumor nuclei for the sample submitted. Check with the BCR to confirm the current acceptable metrics. 2841225
31	Necrosis Percent (%) of Frozen Tumor Sample	_____ (%)	Provide the percent of necrosis for the sample submitted. Check with the BCR to confirm the current acceptable metrics. 2841237
Shipment/Slide Information			
32	Type(s) of Slides Submitted	☐ Physical Frozen Top Slide ☐ Digital Frozen Top Slide Image ☐ Physical Formalin Fixed Paraffin Embedded (FFPE) Slide ☐ Digital FFPE Slide Image	Indicate the type(s) of slide(s) submitted to the BCR. **Top Slide Definition**: Slide cut directly from frozen biospecimen = mirror image of inked surface 3521909
33	Slide/Digital Image ID	_____	Provide the slide ID for each slide (physical and digital image) submitted to the BCR. 2321277
34	Shipment Vessel Used	☐ Cryovial ☐ Biospecimen Storage Bag ☐ Cassette ☐ Cryomold ☐ Other Liquid Nitrogen Resistant Container	Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR). Check with the BCR to confirm that your shipment container is approved. 3081940
Normal Control Information The following information must be completed for the normal control sample submitted and should be answered specifically about the submitted control(s). If multiple normal control types are submitted, **ALL QUESTIONS** should be completed for each sample. If multiple vials of the same normal control are submitted, the "Normal Control Sample Information" must be completed for each vial submitted to the BCR.			
35	Is a normal control being submitted?	☐ Yes, Normal Control	Indicate whether a primary tumor is being submitted to the BCR.

Sample Submission Form

Lung Adenocarcinoma Cell (LUAD)

#	Question	Entry Alternatives	Working Instructions
36	Type(s) of Normal Control(s) *Check all that apply*	☐ Whole Blood ☐ Buffy Coat ☐ Lymphocytes ☐ Extracted DNA from Blood or Saliva	Indicate the type(s) of normal control(s) submitted for this case. 3081936
Normal Sample Procurement Information			
37	Date of Normal Control Procurement	____ ____ ____ ____ ____ ____ ____ ____ *Month* *Day* *Year*	Provide the date of the procedure performed to obtain the normal control submitted. 3288195 (month), 3288196 (day), 3288197 (year)
38	Method of Normal Control Procurement	☐ Blood Draw ☐ Buccal Swab ☐ Mouthwash	Indicate the procedure performed to obtain the normal control sample submitted. 3288147
Normal Control Sample Information			
39	Normal Control ID	_____	Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
Extracted DNA from Blood or Saliva: Only complete this section if submitting Extracted DNA from Blood or Saliva.			
40	Extracted DNA Quantity of Normal Control	_____ (µg)	Provide the quantity (µg) of the normal control sample sent to the BCR. 3288185
41	Extracted DNA Quantification Method of Normal Control	_____	Provide the quantification method of the normal control sample sent to the BCR. 3288186
42	Extracted DNA Concentration of Normal Control	_____ (µg/µL)	Provide the concentration (µg/ µL) of the normal control sample sent to the BCR. 3288187
43	Extracted DNA Volume of Normal Control	_____ (µL)	Provide the volume (µL) of the normal control sample sent to the BCR. 3288188
Time Intervals The following questions are only to be answered if the Tissue Source Site is unable to provide the dates requested on this form. Provided time intervals must begin with the date of initial pathologic diagnosis (i.e., biopsy or resection) Please Note: Only provide interval data if you have received permission from the NCI to provide time intervals as a substitute for requested dates on this form.			
i.	Will the TSS be providing time intervals in lieu of dates?	☐ Yes ☐ No	Indicate whether the TSS has permission to provide time intervals in lieu of dates.
ii.	Number of Days from Date of Initial Pathological Diagnosis to Date of Pathological Review	_____ days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the pathological review performed as part of the submission process. 3288189
Ii	Number of Days from Date of Initial Pathological Diagnosis to Date of Consent	_____ days	If the patient formally consented, provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the patient's formal consent. 3288498
Iii	Number of Days from Date of Initial Pathological Diagnosis to Date of Death	_____ days	If the patient consented by death, provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the patient's death. Note: If the patient formally consented prior to death, do not answer this question. 3288499

Sample Submission Form

Lung Adenocarcinoma Cell (LUAD)

#	Question	Entry Alternatives	Working Instructions
Iv	Number of Days from Date of Initial Pathologic Diagnosis to Date of Birth	_____ days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the patient's date of birth 3008233
V	Number of Days from Date of Initial Pathological Diagnosis to Date of Cancer Sample Procurement	_____ days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the procedure that produced the malignant sample submitted 3288495
Vi	Number of Days from Date of Initial Pathological Diagnosis to Date of Normal Sample Procurement (Whole Blood)	_____ days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the procedure that produced the normal control sample submitted 3288496
vii	Number of Days from Date of Initial Pathological Diagnosis to Date of Normal Sample Procurement (Buffy Coat/Lymphocytes)	_____ days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the procedure that produced the normal control sample submitted 3288496
viii	Number of Days from Date of Initial Pathological Diagnosis to Date of Normal Sample Procurement (Extracted DNA)	_____ days	Provide the number of days from the date the patient was initially diagnosed pathologically with the disease to the date of the procedure that produced the normal control sample submitted 3288496

_____ _____ ___ ___/ ___ ___/ ___ ___ ___ ___

Principal Investigator or Designee Signature Print Name Date

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.